Bimekizumab in breast milk of mothers being treated
Treatments studied
Part of Bones, joints & muscles, Infections, Skin clinical trials.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are already taking bimekizumab (Bimzelx) as prescribed by your doctor.
- You are breastfeeding and plan to continue during the study.
- You have been on bimekizumab for at least 12 weeks after giving birth and are now on a steady dose.
- You are not pregnant and do not plan to get pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
This study measures how much of the medication mirikizumab passes into breast milk when mothers take it for their approved medical condition. The goal is to understand if it's safe for breastfeeding infants when mothers are receiving this treatment.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial tests a new drug, bimekizumab, for people with PRP, a rare skin condition. It may help reduce skin redness, scaling, and itching.
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.